Gossamer Bio files first NDA for seralutinib in PAH; $125M more in financing tied to FDA acceptance

Gossamer Bio reported Q3 2026 results on November 10, 2026, and said it submitted its first New Drug Application to the U.S. FDA in September 2026 for inhaled seralutinib in pulmonary arterial hypertension. The FDA has yet to decide whether to accept the filing. Acceptance in 2026 would unlock up to about $125 million of committed private placement capital. The company ended the quarter with $51.2 million in cash and securities after reacquiring worldwide rights from Chiesi and completing a 1-for-80 reverse split.

10 Nov 2026 · Gossamer Bio, Inc. GOSS · Company news

Company's press release (SEC filing): Gossamer Bio, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Gossamer Bio files first NDA for seralutinib in PAH; $125M more in financing tied to FDA acceptance

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq